Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19

Published:2023-09 Issue:3 Volume:62 Page:106920
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Palmer Mary E.^ORCID,Belcher Rachel M.^ORCID,Engeleit Anastasia,Wenzler Eric^ORCID,Bulman Zackery P.^ORCID,Benken Scott T.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference14 articles.

1. Baricitinib [package insert]. https://uspl.lilly.com/olumiant/olumiant.html#pi. Indianapolis, Indiana: Eli Lilly; 2022.

2. Baricitinib is first approved COVID-19 immunomodulatory treatment;Rubin;JAMA,2022

3. Baricitinib plus remdesivir for hospitalized adults with COVID-19;Kalil;N Eng J Med,2021

4. Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER): a randomized, double-blind, parallel-group, placebo-controlled phase 3 trial;Marconi;Lancet Respir Med,2021

5. Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19;Peterson;Crit Care Med,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP